These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

263 related items for PubMed ID: 9829299

  • 1. Comparison of intrastriatal injections of quinolinic acid and 3-nitropropionic acid for use in animal models of Huntington's disease.
    Shear DA, Dong J, Gundy CD, Haik-Creguer KL, Dunbar GL.
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Oct; 22(7):1217-40. PubMed ID: 9829299
    [Abstract] [Full Text] [Related]

  • 2. Quinolinic acid released from polymeric brain implants causes behavioral and neuroanatomical alterations in a rodent model of Huntington's disease.
    Haik KL, Shear DA, Schroeder U, Sabel BA, Dunbar GL.
    Exp Neurol; 2000 Jun; 163(2):430-9. PubMed ID: 10833318
    [Abstract] [Full Text] [Related]

  • 3. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats.
    Figueredo-Cardenas G, Anderson KD, Chen Q, Veenman CL, Reiner A.
    Exp Neurol; 1994 Sep; 129(1):37-56. PubMed ID: 7925841
    [Abstract] [Full Text] [Related]

  • 4. Chronic administration of quinolinic acid in the rat striatum causes spatial learning deficits in a radial arm water maze task.
    Shear DA, Dong J, Haik-Creguer KL, Bazzett TJ, Albin RL, Dunbar GL.
    Exp Neurol; 1998 Apr; 150(2):305-11. PubMed ID: 9527900
    [Abstract] [Full Text] [Related]

  • 5. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease.
    Roitberg BZ, Emborg ME, Sramek JG, Palfi S, Kordower JH.
    Neurosurgery; 2002 Jan; 50(1):137-45; discussion 145-6. PubMed ID: 11844244
    [Abstract] [Full Text] [Related]

  • 6. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats.
    Borlongan CV, Koutouzis TK, Randall TS, Freeman TB, Cahill DW, Sanberg PR.
    Brain Res Bull; 1995 Jan; 36(6):549-56. PubMed ID: 7538873
    [Abstract] [Full Text] [Related]

  • 7. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid.
    Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT.
    J Neurosci; 1993 Oct; 13(10):4181-92. PubMed ID: 7692009
    [Abstract] [Full Text] [Related]

  • 8. Quantifiable bradykinesia, gait abnormalities and Huntington's disease-like striatal lesions in rats chronically treated with 3-nitropropionic acid.
    Guyot MC, Hantraye P, Dolan R, Palfi S, Maziére M, Brouillet E.
    Neuroscience; 1997 Jul; 79(1):45-56. PubMed ID: 9178864
    [Abstract] [Full Text] [Related]

  • 9. 3-Nitropropionic acid induces a spectrum of Huntington's disease-like neuropathology in rat striatum.
    Vis JC, Verbeek MM, De Waal RM, Ten Donkelaar HJ, Kremer HP.
    Neuropathol Appl Neurobiol; 1999 Dec; 25(6):513-21. PubMed ID: 10632901
    [Abstract] [Full Text] [Related]

  • 10. Intrastriatal 3-nitropropionic acid: a behavioral assessment.
    Koutouzis TK, Borlongan CV, Freeman TB, Cahill DW, Sanberg PR.
    Neuroreport; 1994 Nov 21; 5(17):2241-5. PubMed ID: 7881036
    [Abstract] [Full Text] [Related]

  • 11. Chronic intrastriatal dialytic administration of quinolinic acid produces selective neural degeneration.
    Bazzett TJ, Becker JB, Kaatz KW, Albin RL.
    Exp Neurol; 1993 Apr 21; 120(2):177-85. PubMed ID: 8387931
    [Abstract] [Full Text] [Related]

  • 12. Probucol modulates oxidative stress and excitotoxicity in Huntington's disease models in vitro.
    Colle D, Hartwig JM, Soares FA, Farina M.
    Brain Res Bull; 2012 Mar 10; 87(4-5):397-405. PubMed ID: 22245028
    [Abstract] [Full Text] [Related]

  • 13. Age-dependent differences in survival of striatal somatostatin-NPY-NADPH-diaphorase-containing interneurons versus striatal projection neurons after intrastriatal injection of quinolinic acid in rats.
    Figueredo-Cardenas G, Chen Q, Reiner A.
    Exp Neurol; 1997 Aug 10; 146(2):444-57. PubMed ID: 9270055
    [Abstract] [Full Text] [Related]

  • 14. Progressive behavioural changes in the spatial open-field in the quinolinic acid rat model of Huntington's disease.
    Scattoni ML, Valanzano A, Popoli P, Pezzola A, Reggio R, Calamandrei G.
    Behav Brain Res; 2004 Jul 09; 152(2):375-83. PubMed ID: 15196806
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Adenosine A2A receptor blockade before striatal excitotoxic lesions prevents long term behavioural disturbances in the quinolinic rat model of Huntington's disease.
    Scattoni ML, Valanzano A, Pezzola A, March ZD, Fusco FR, Popoli P, Calamandrei G.
    Behav Brain Res; 2007 Jan 25; 176(2):216-21. PubMed ID: 17123640
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of rutin against a mitochondrial toxin, 3-nitropropionicacid induced biochemical, behavioral and histological alterations-a pilot study on Huntington's disease model in rats.
    Suganya SN, Sumathi T.
    Metab Brain Dis; 2017 Apr 25; 32(2):471-481. PubMed ID: 27928694
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.